218933-36-9

Upstream product

• 5192-23-4 4-amino-1H-indole 
• 55-51-6 N,N-bis(2-chloro-ethyl)-benzenemethanamine 
• 479080-93-8 1-triisopropylsilanyl-4-(4-benzyl-piperazin-1-yl)-1H-indole 
• 10429-82-0 N-benzyl-2-chloro-N-(2-chloroethyl)ethanamine hydrochloride 

Downstream Products

• 218933-43-8 4-(4-Benzyl-piperazin-1-yl)-3-bromo-1H-indole 
• 218933-42-7 4-(4-Benzyl-piperazin-1-yl)-3,5-dichloro-1H-indole 

Relevant academic research and scientific papers

5HT7 receptor ligands and compositions comprising the same

The present invention relates to compounds having pharmacological activity towards the 5-HT7 receptor, especially as agonists, identified by using a pharmacophore and a descriptor's profile filter as well as to pharmaceutical compositions comprising them. These compounds are useful in therapy in particular for the treatment and or prophylaxis of a disease in which 5-HT7 is involved, such as CNS disorders.

4-piperazinylindole derivatives with 5-HT6 receptor affinity

This invention relates to compounds which have generally 5-HT6 receptor affinity and which are represented by Formula I: wherein R3 is SO2—Ar, Ar is aryl or heteroaryl; and R1, R2, R4 and R5 /su

New generation dopaminergic agents. 5. Heterocyclic bioisosteres that exploit the 3-OH-N1-phneylpiperazine dopaminergic template

The synthesis of several bioisoteric analogs based on the 3-OH-N1- phenylpiperazine dopamine D2 agonist template (i.e., 4) is described. The indolone (5) and 2-CF3-benzimidazole (13) were observed to have excellent affinity for the D2 receptor. Several D4 selective compounds were also identified. Molecular modeling studies and a putative bioactive conformation are discussed.